Apr 26, 2019 - Sanofi's first-quarter 2019 results were mixed as it beat estimates for earnings but missed the same for sales.
Apr 25, 2019 - Bayer (BAYRY) exceeds earnings estimates in the first quarter of 2019 and sales rise year over year.
Apr 23, 2019 - AstraZeneca (AZN) will report first-quarter results on Apr 26. New drugs likely to drive sales.
Apr 18, 2019 - AVEO Pharmaceuticals (AVEO) suffers a major hindrance as it defers its NDA filing for Fotivda in the United States.
Apr 17, 2019 - Top Ranked Income Stocks to Buy for April 17th
Apr 15, 2019 - Clovis Oncology (CLVS) halts mid-stage bladder cancer study evaluating Rubraca monotherapy. It is unlikely to provide meaningful clinical benefit as reviewed by an independent data monitoring committee.
Apr 12, 2019 - Glaxo (GSK) gets FDA approval for a new HIV medicine, Dovato. AstraZeneca (AZN)/Merck's (MRK) Lynparza gets approval in EU for metastatic breast cancer.
Apr 10, 2019 - Alkermes (ALKS) reports positive top-line data from phase IIIb study evaluating Aristada and Invega Sustenna in patients with acute exacerbations of schizophrenia.
Apr 10, 2019 - AstraZeneca (AZN) and Merck gain an EU approval for Lynparza as a monotherapy for treating HER2-negative locally-advanced/metastatic breast cancer.
Apr 09, 2019 - FDA grants PhaseBio's (PHAS) lead pipeline candidate, PB2452, Breakthrough Therapy status for treating bleeding risk associated with, AstraZeneca's antiplatelet drug Brilinta.